Unverified50% confidenceFactExact time
Academic research has shown that AI can design molecules whose sequences differ greatly from dangerous pathogens in databases yet fold into equally harmful proteins, thereby circumventing existing screening by DNA synthesis companies.
1
Sources
50%
Confidence
Long-term
Relevance
10/4/2026
First Seen
Sources
Related Entities
Related Claims
UnverifiedSequence-based AI models can handle non-coding regulatory variants, unlike earlier tools that focused only on amino acid changes in coding regions.75% similarUnverifiedThe application of artificial intelligence in protein structure prediction, target screening, and clinical trial design is compressing the drug development cycle.72% similarUnverifiedThe core technical approach of AI genomics tools typically involves integrating multi-omics data (such as ATAC-seq, ChIP-seq, and Hi-C) to train models to learn how sequence changes affect regulatory activity.71% similarVerifiedRisks in the biological domain are primarily concentrated in AI-assisted synthetic biology, namely using models to lower the knowledge barriers to designing or acquiring dangerous biological agents.71% similar
Cite This Claim
Stable URI
https://kongchang.com/claim/972908API
curl https://kongchang.com/api/v1/knowledge/claims/972908MCP
get_claim(id=972908)